Review: taking Pepcid ac and Vyvanse together


Summary

Drug interactions are reported among people who take Pepcid ac and Vyvanse together. This review analyzes the effectiveness and drug interactions between Pepcid ac and Vyvanse. It is created by eHealthMe based on reports of 12 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Pepcid ac and Vyvanse >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Pepcid Ac

Pepcid ac has active ingredients of famotidine. It is often used in gastrooesophageal reflux disease. (latest outcomes from Pepcid ac 3,423 users)

Vyvanse

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Vyvanse 8,615 users)

On Aug, 22, 2016

12 people who take Pepcid Ac, Vyvanse are studied.


Number of reports submitted per year:

Pepcid ac and Vyvanse drug interactions.

Drug effectiveness over time:

Pepcid Ac:
  • < 1 month: 100.0% - (2 of 2 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 100.0% - (1 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Vyvanse:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Pepcid Ac:
  • female: 100.0% - (1 of 1 people)
  • male: 100.0% - (2 of 2 people)
Vyvanse:
  • female: 100.0% - (1 of 1 people)
  • male: 100.0% - (2 of 2 people)

Drug effectiveness by age:

Pepcid Ac:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 100.0% - (2 of 2 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)
Vyvanse:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 100.0% - (2 of 2 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • cramps - leg
1 - 2 years:
  • blood amylase increased
  • cramps - leg
10+ years:
  • blood amylase increased
not specified:
  • abdominal discomfort
  • blindness unilateral
  • eye infection
  • gait disturbance
  • asthenia
  • eye irritation
  • eye pain
  • headache
  • migraine
  • ear infection

Most common drug interactions by gender *:

female:
  • asthenia
  • eye irritation
  • eye pain
  • headache
  • migraine
  • ear infection
  • abdominal discomfort
  • blindness unilateral
  • eye infection
  • gait disturbance
male:
  • apparent death
  • blood amylase increased
  • cramps - leg
  • dyspnoea
  • eye swelling
  • laryngeal oedema
  • lip swelling
  • oedema mouth
  • pharyngeal oedema
  • swelling face

Most common drug interactions by age *:

10-19:
  • abdominal discomfort
  • asthenia
  • blindness unilateral
  • ear infection
  • eye infection
  • eye irritation
  • eye pain
  • headache
  • migraine
  • nausea
20-29:
  • anxiety
  • attention deficit/hyperactivity disorder
  • cerebrovascular accident
  • cognitive disorder
  • dysphagia
  • fungal infection
  • hypercoagulation
  • impaired self-care
  • mobility decreased
  • urinary retention
30-39:
  • ear infection
  • injection site erythema
  • injection site reaction
  • injection site swelling
  • injection site warmth
40-49:
  • blood amylase increased
  • cramps - leg
50-59:
  • eye irritation
  • eye pain
  • gait disturbance
  • headache
  • infusion related reaction
  • migraine
  • myalgia
  • tendonitis
  • visual field defect
  • asthenia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Pepcid ac and Vyvanse?

Can you answer these questions?

More questions for: Pepcid ac, Vyvanse

You may be interested in these reviews

More reviews for: Pepcid ac, Vyvanse

On eHealthMe, Pepcid ac (famotidine) is often used to treat gastrooesophageal reflux disease. Vyvanse (lisdexamfetamine dimesylate) is often used to treat attention deficit hyperactivity disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.